{{Short description|Chemical compound}} {{Use dmy dates|date=December 2024}} {{cs1 config |display-authors=6}} {{Infobox drug | image = Cagrilintide.png | image_class = skin-invert-image | alt = | caption =

<!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = | ATC_prefix = None | ATC_suffix =

<!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US_comment = | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion =

<!-- Identifiers --> | CAS_number = 1415456-99-3 | UNII = AO43BIF1U8 | PubChem = 167312356 | DrugBank = DB18887 | ChemSpiderID = 129424923 | synonyms = GLXC-26801

<!-- Chemical and physical data --> | IUPAC_name = <nowiki>20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2R)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid</nowiki> | chemical_formula = | molecular_weight = | StdInChI=1S/C194H312N54O59S2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209)/t100-,101-,102-,103-,104+,105+,106+,107+,108+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-,154-,155-,156-/m0/s1 | StdInChIKey = LDERDVMBIYGIOI-DDPFBLHVSA-N | SMILES = CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O }}

'''Cagrilintide''' is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide ("CagriSema").<ref>{{cite journal |last1=Larsen |first1=Anna T. |last2=Sonne |first2=Nina |last3=Mohamed |first3=Khaled Elhady |last4=Bredtoft |first4=Emma-Marie |last5=Andersen |first5=Frederik |last6=Karsdal |first6=Morten A. |last7=Henriksen |first7=Kim |title=823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats |journal=Diabetes |date=1 June 2022 |volume=71 |issue=Supplement_1 |doi=10.2337/db22-823-P |s2cid=249259033 |url=https://diabetesjournals.org/diabetes/article/71/Supplement_1/823-P/146339|url-access=subscription }}</ref><ref>{{cite journal |last1=Lau |first1=David C W |last2=Erichsen |first2=Lars |last3=Francisco |first3=Ann Marie |last4=Satylganova |first4=Altynai |last5=le Roux |first5=Carel W |last6=McGowan |first6=Barbara |last7=Pedersen |first7=Sue D |last8=Pietiläinen |first8=Kirsi H |last9=Rubino |first9=Domenica |last10=Batterham |first10=Rachel L |title=Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial |journal=The Lancet |date=December 2021 |volume=398 |issue=10317 |pages=2160–2172 |doi=10.1016/S0140-6736(21)01751-7 |pmid=34798060 |s2cid=244169045 |url=https://discovery.ucl.ac.uk/id/eprint/10155031/ |language=en}}</ref><ref>{{cite journal |last1=Kruse |first1=Thomas |last2=Hansen |first2=Jakob Lerche |last3=Dahl |first3=Kirsten |last4=Schäffer |first4=Lauge |last5=Sensfuss |first5=Ulrich |last6=Poulsen |first6=Christian |last7=Schlein |first7=Morten |last8=Hansen |first8=Ann Maria Kruse |last9=Jeppesen |first9=Claus Bekker |last10=Dornonville de la Cour |first10=Charlotta |last11=Clausen |first11=Trine Ryberg |last12=Johansson |first12=Eva |last13=Fulle |first13=Simone |last14=Skyggebjerg |first14=Rikke Bjerring |last15=Raun |first15=Kirsten |title=Development of Cagrilintide, a Long-Acting Amylin Analogue |journal=Journal of Medicinal Chemistry |date=12 August 2021 |volume=64 |issue=15 |pages=11183–11194 |doi=10.1021/acs.jmedchem.1c00565 |pmid=34288673 |s2cid=236175929 |language=en |issn=0022-2623|doi-access=free }}</ref><ref>{{cite journal |last1=Frias |first1=Juan P |last2=Deenadayalan |first2=Srikanth |last3=Erichsen |first3=Lars |last4=Knop |first4=Filip K |last5=Lingvay |first5=Ildiko |last6=Macura |first6=Stanislava |last7=Mathieu |first7=Chantal |last8=Pedersen |first8=Sue D |last9=Davies |first9=Melanie |title=Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial |journal=The Lancet |date=August 2023 |volume=402 |issue=10403 |pages=720–730 |doi=10.1016/S0140-6736(23)01163-7 |pmid=37364590 |s2cid=259237278 |language=en}}</ref><ref>{{cite journal |last1=D'Ascanio |first1=Antonella M. |last2=Mullally |first2=Jamie A. |last3=Frishman |first3=William H. |title=Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity |journal=Cardiology in Review |date=8 March 2023 |volume=32 |issue=Publish Ahead of Print |pages=83–90 |doi=10.1097/CRD.0000000000000513 |pmid=36883831 |s2cid=257404657 }}</ref><ref>{{cite journal |last1=Larsen |first1=A. T. |last2=Mohamed |first2=K. E. |last3=Sonne |first3=N. |last4=Bredtoft |first4=E. |last5=Andersen |first5=F. |last6=Karsdal |first6=MA |last7=Henriksen |first7=K. |title=Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models |journal=Biomedicine & Pharmacotherapy |date=1 December 2022 |volume=156 |article-number=113842 |doi=10.1016/j.biopha.2022.113842 |pmid=36242844 |s2cid=252881350 |issn=0753-3322 |doi-access=free}}</ref>

== Research == A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.<ref>{{cite journal | vauthors = Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, Kamrul-Hasan A | title = Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis | journal = Indian Journal of Endocrinology and Metabolism | volume = 28 | issue = 5 | pages = 436–444 | date = 2024 | pmid = 39676787 | pmc = 11642503 | doi = 10.4103/ijem.ijem_45_24 | doi-access = free | title-link = doi }}</ref>

Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study,<ref>{{cite web | url = https://clinicaltrials.gov/study/NCT05567796 | title = REDEFINE 1}}</ref> cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment. In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss ≥15%, compared to approximately 1 in 20 participants (4.7%) who received placebo.<ref>{{cite journal | vauthors = Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Lehmann EW, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JP | title = Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | journal = New England Journal of Medicine | volume = 393 | issue = 7 | pages = 635–647 | date = 2025 | pmid = 40544433 | doi = 10.1056/NEJMoa2502081 | doi-access = free | title-link = doi}}</ref>

==References== {{reflist}}

{{Portal bar | Medicine}} {{Authority control}}

Category:Amylin receptor agonists Category:Experimental diabetes drugs Category:Cyclic peptides Category:Peptide therapeutics